140 related articles for article (PubMed ID: 34918553)
1. Androgen Deprivation Therapy and the Risk for Inguinal Hernia: An Observational Nested Case Control Study.
Hermann M; Vikman H; Stattin P; Katawazai A; Gustafsson O; Styrke J; Sandblom G
Am J Mens Health; 2021; 15(6):15579883211058606. PubMed ID: 34918553
[TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care.
Martín-Merino E; Johansson S; Morris T; García Rodríguez LA
Drug Saf; 2011 Nov; 34(11):1061-77. PubMed ID: 21981434
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.
Lapi F; Azoulay L; Niazi MT; Yin H; Benayoun S; Suissa S
JAMA; 2013 Jul; 310(3):289-96. PubMed ID: 23860987
[TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation therapy, comorbidity, cancer stage and mortality from COVID-19 in men with prostate cancer.
Gedeborg R; Lindhagen L; Loeb S; Styrke J; Garmo H; Stattin P
Scand J Urol; 2022 Apr; 56(2):104-111. PubMed ID: 34939533
[TBL] [Abstract][Full Text] [Related]
5. Risk of colorectal adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer; a nationwide cohort study.
Shore R; Zhang J; Ye W; Stattin P; Lindblad M
Cancer Causes Control; 2023 Nov; 34(11):949-961. PubMed ID: 37341814
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation therapy in men with prostate cancer is not associated with COVID-2019 infection.
Davidsson S; Messing Eriksson A; Udumyan R; Swanholm P; Lewin Lundh M; Widing C; Lindlöf C; Fridfeldt J; Andersson SO; Fall K
Prostate; 2023 May; 83(6):555-562. PubMed ID: 36658755
[TBL] [Abstract][Full Text] [Related]
7. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation therapy for prostate cancer and risk of dementia.
Robinson D; Garmo H; Van Hemelrijck M; Damber JE; Bratt O; Holmberg L; Wahlund LO; Stattin P; Adolfsson J
BJU Int; 2019 Jul; 124(1):87-92. PubMed ID: 30637900
[TBL] [Abstract][Full Text] [Related]
9. Androgen Deprivation Therapy for Prostate Cancer Did Not Increase the Risk of Retinal Vascular Occlusion: A Population-Based Cohort Study.
Lin HL; Lee CY; Huang JY; Tseng PC; Yang SF
Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206456
[TBL] [Abstract][Full Text] [Related]
10. Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score-matched longitudinal cohort study.
Wu YH; Jhan JH; Ke HL; Tseng SI; Chang YH; Yeh HC; Li CC; Lee YC
Int J Clin Pharm; 2020 Dec; 42(6):1433-1439. PubMed ID: 32951178
[TBL] [Abstract][Full Text] [Related]
11. Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures-a study from the fractures and fall injuries in the elderly cohort (FRAILCO).
Wallander M; Axelsson KF; Lundh D; Lorentzon M
Osteoporos Int; 2019 Jan; 30(1):115-125. PubMed ID: 30324413
[TBL] [Abstract][Full Text] [Related]
12. Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer.
Shahinian VB; Kuo YF
J Gen Intern Med; 2013 Nov; 28(11):1440-6. PubMed ID: 23670565
[TBL] [Abstract][Full Text] [Related]
13. Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer.
Ong WL; Foroudi F; Evans S; Millar J
BJU Int; 2017 Nov; 120 Suppl 3():35-42. PubMed ID: 28749017
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer.
Yang DD; Krasnova A; Nead KT; Choueiri TK; Hu JC; Hoffman KE; Yu JB; Spratt DE; Feng FY; Trinh QD; Nguyen PL
Ann Oncol; 2018 Feb; 29(2):386-391. PubMed ID: 29267861
[TBL] [Abstract][Full Text] [Related]
15. Retrospective cohort study of androgen deprivation therapy and the risk of diabetes in men with prostate cancer in Lithuania.
Drevinskaite M; Patasius A; Kincius M; Urbonas V; Smailyte G
BMJ Open; 2021 Jul; 11(7):e045797. PubMed ID: 34321292
[TBL] [Abstract][Full Text] [Related]
16. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S
J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050
[TBL] [Abstract][Full Text] [Related]
17. National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer.
Yang DD; Muralidhar V; Mahal BA; Labe SA; Nezolosky MD; Vastola ME; King MT; Martin NE; Orio PF; Choueiri TK; Trinh QD; Spratt DE; Hoffman KE; Feng FY; Nguyen PL
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):338-343. PubMed ID: 28463152
[TBL] [Abstract][Full Text] [Related]
18. New-onset diabetes after androgen-deprivation therapy for prostate cancer: A nationwide propensity score-matched four-year longitudinal cohort study.
Jhan JH; Yeh HC; Chang YH; Guu SJ; Wu WJ; Chou YH; Li CC
J Diabetes Complications; 2018 Jul; 32(7):688-692. PubMed ID: 29909141
[TBL] [Abstract][Full Text] [Related]
19. Androgens and prostate cancer; pathogenesis and deprivation therapy.
Grossmann M; Cheung AS; Zajac JD
Best Pract Res Clin Endocrinol Metab; 2013 Aug; 27(4):603-16. PubMed ID: 24054933
[TBL] [Abstract][Full Text] [Related]
20. The use of androgen deprivation therapy for prostate cancer and its effect on the subsequent dry eye disease: a population-based cohort study.
Chien HW; Lin CW; Lee CY; Huang JY; Yang SF; Wang K
Int J Med Sci; 2022; 19(7):1103-1109. PubMed ID: 35919811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
